Thinly traded nano cap VIVUS (NASDAQ:VVUS) is up 25% premarket in reaction to FDA approval of a new formulation of Pancreaze (pancrelipase) with a 36-month shelf life across all dosages.
https://seekingalpha.com/news/3538466-vivus-up-25-premarket-on-fda-nod-for-improved-formulation-of-pancreaze
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.